drugset / Trial / NCT03033160
Vaginal Estrogen for Asymptomatic Microscopic Hematuria
Phase 4
Unknown
68 enrolled
Boston Urogynecology Associates
Beth Israel Deaconess Medical Center · collabMount Auburn Hospital · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The specific aim of this protocol is to determine whether vaginal estrogen is an effective treatment for asymptomatic microscopic hematuria in postmenopausal women. The investigators hypothesize that women who use vaginal estrogen for three months will be more likely to have resolution of their asymptomatic microscopic hematuria compared with women who do not use vaginal estrogen.
Timeline
- Start
- 2016-12
- Primary completion
- 2019-10
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 2 mg | Other |
Indications
No indication recorded.